New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
06:22 EDTTSROTESARO upgraded to Outperform from Market Perform at BMO Capital
Price target raised to $46 from $36.
News For TSRO From The Last 14 Days
Check below for free stories on TSRO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 10, 2014
09:20 EDTTSROTESARO management to meet with Leerink
Subscribe for More Information
September 8, 2014
12:22 EDTTSROOPKO reports licensee TESARO submits NDA for Rolapitant
Subscribe for More Information
08:10 EDTTSROTESARO submits rolapitant NDA to FDA
TESARO announced that it has submitted the New Drug Application, or NDA, for oral rolapitant to the FDA. Rolapitant is an investigational neurokinin-1 receptor antagonist developed for the prevention of chemotherapy-induced nausea and vomiting.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use